Funded Startups in Évry
Among Évry-based funded startups shown here (6 rows), Abolis Biotechnologies’ $39M round on 2024-09-12 stands out as the only disclosed amount far above th…
Among Évry-based funded startups shown here (6 rows), Abolis Biotechnologies’ $39M round on 2024-09-12 stands out as the only disclosed amount far above the rest; the next-largest disclosed figure is Global Bioenergies’ $10M (2023-10-04), while the remaining disclosed rounds cluster at $6M or below (Formal ity $6M on 2024-10-02, ex9 $2M on 2025-07-09, PEP-Therapy $2M on 2021-07-19, and Enalees $490K on 2022-10-24). Sector concentration is also clear: biotechnology appears in 3 of 6 entries (Abolis Biotechnologies, Global Bioenergies, PEP-Therapy), and health care adds a further non-bio foothold with Enalees (2022-10-24, $490K). Temporally, the dataset spans from PEP-Therapy’s 2021-07-19 Series A to ex9’s most recent 2025-07-09 Seed, and 4 of 6 rounds fall between 2023-10-04 and 2024-10-02, indicating a tight late-2023 through 2024 window.
Most recent rounds
6 shownRelated listings
Frequently asked
Which Évry company has the largest disclosed funding in this set, and how extreme is it versus the other disclosed rounds?
Abolis Biotechnologies’ disclosed $39M (2024-09-12) dwarfs the rest; Global Bioenergies is next at $10M (2023-10-04), followed by Formality at $6M (2024-10-02), with the remaining disclosed amounts at $2M (ex9 on 2025-07-09; PEP-Therapy on 2021-07-19) and $490K (Enalees on 2022-10-24).
Do these records cluster in a particular time window rather than being evenly spread?
Yes. 4 of 6 rounds land between 2023-10-04 (Global Bioenergies) and 2024-10-02 (Formality), including Abolis Biotechnologies ($39M, 2024-09-12) and ex9 is the only entry outside that window on 2025-07-09 ($2M).
Which sectors are most over-represented across the 6 entries?
Biotechnology is the standout at 3 of 6 entries: Abolis Biotechnologies ($39M, 2024-09-12), Global Bioenergies ($10M, 2023-10-04), and PEP-Therapy ($2M, 2021-07-19). The other sectors appear once each across this slice: Manufacturing (ex9), Health Care (Enalees), and Professional Services (Formality).
Is the stage mix dominated by a single classification, or are multiple stages represented?
The stage values are split, with “Series Unknown” appearing in 2 of 6 entries (Abolis Biotechnologies on 2024-09-12 at $39M; Global Bioenergies on 2023-10-04 at $10M). The remaining 4 entries are distributed across Seed (ex9 $2M on 2025-07-09; Formality $6M on 2024-10-02), Grant (Enalees $490K on 2022-10-24), and Series A (PEP-Therapy $2M on 2021-07-19).
Are there outliers in either funding size or sector that would warrant separate diligence?
Funding size is the main outlier: Abolis Biotechnologies’ $39M (2024-09-12) is far above the next-largest disclosed amount of $10M (Global Bioenergies, 2023-10-04). Sector-wise, biotechnology forms a cluster (3 entries), while Manufacturing (ex9) and Professional Services (Formality) each appear only once, making those non-biotech entries useful comparators.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.